Form 4: Alnylam Pharmaceuticals Executive Acquires Shares Through Restricted Stock Units

Robert W. Hesslein, EVP, CLO and Secretary of Alnylam Pharmaceuticals, acquired 7,245 shares of common stock through restricted stock units (RSUs) on October 1, 2024.

Summary

• On October 1, 2024, Robert W. Hesslein, an executive at Alnylam Pharmaceuticals, acquired 7,245 shares of common stock.
• The acquisition was made through restricted stock units (RSUs) granted under the company's Amended and Restated 2018 Stock Incentive Plan.
• Each RSU represents a contingent right to receive one share of common stock.
• The RSUs vest over a three-year period, with one-third vesting annually on the anniversary of the grant date, contingent upon continuous service with the Issuer.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive as it reflects an executive increasing their stake in the company, which is generally seen as a sign of confidence. However, it's a routine transaction related to compensation.

Positives

• The acquisition of shares by an executive demonstrates confidence in the company's future.

Future Outlook

The RSUs will vest over a three-year period, contingent upon continuous service with the Issuer.

Industry Context

Form 4 filings are standard practice and provide transparency into the transactions of company insiders.

Stakeholder Impact

• The acquisition of shares by an executive could have a slightly positive impact on shareholder sentiment.

Key Dates